Recent developments in the HIV neuropathiesLuciano, Carlos A.a; Pardo, Carlos A.b,c; McArthur, Justin C.b,dCurrent Opinion in Neurology: June 2003 - Volume 16 - Issue 3 - p 403-409 Inflammatory diseases Abstract Author Information Purpose of review With the introduction of highly active antiretroviral therapy peripheral neuropathies have become the most common neurological complications in HIV infection. The frequency and spectrum of these neuropathies are changing, as the various toxic and immune factors are modified by new treatment strategies. Recent studies have provided a better understanding of the risk factors, markers and relevant pathogenic mechanisms, and a thorough review of these is critical for an improved understanding of this important and increasingly common complication. Recent findings The combined use of dideoxynucleosides, in association with immune-mediated mechanisms triggered by HIV infection, are critical in the development of distal sensory polyneuropathy. Valuable markers of neuropathy such as intraepidermal nerve fiber density from skin biopsies have been validated and promise to be a valuable tool in the detection and monitoring of distal sensory polyneuropathy. Markers of virological activity have also been associated with the severity of neuropathic pain in distal sensory polyneuropathy. In some instances, the enhanced viral suppression from antiretroviral agents may actually improve or decrease the frequency of certain types of neuropathy. New evidence supports mitochondrial toxicity as a principal mechanism for dideoxynucleoside-associated sensory neuropathy, and questions arise about enhanced risk with pre-existing mitochondrial defects. Confirmed treatments are limited to the reduction of symptoms, with a need for the further investigation of corrective therapies. Summary Increased and improved surveillance for HIV-associated neuropathy will allow earlier interventions to improve quality of life and prevent severe toxicities. A better understanding of the prevailing mechanisms will allow for more effective interventions. aSpecialized Neuroscience Research Program in NeuroAIDS, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico; and Departments of bNeurology, cPathology and dEpidemiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA Correspondence to Carlos A. Luciano, MD, RCMI - Clinical Research Center, University of Puerto Rico Medical Sciences Campus, PO Box 365067, San Juan, Puerto Rico 00936-5067 Tel: +1 787 759 0306; fax: +1 787 759 0305; e-mail: email@example.com © 2003 Lippincott Williams & Wilkins, Inc.